Marketing


  • Vials of Eisai and Biogen's new Alzheimer's drug Leqembi
    Image attribution tooltip
    Courtesy of Eisai
    Image attribution tooltip
    New Alzheimer's drugs

    Eisai’s Alzheimer’s drug Leqembi approved in Japan

    Eisai and Biogen’s anti-amyloid drug is still undergoing regulatory reviews in the EU, U.K. and elsewhere.

    By Sept. 25, 2023
  • Human respiratory syncytial virus virions are shedding from the surface of human lung cells.
    Image attribution tooltip
    National Institute of Allergy and Infectious Diseases. (2017). "Human Respiratory Syncytial Virus" [Micrograph]. Retrieved from Flickr.
    Image attribution tooltip

    New RSV vaccines can be powerful tools, but rollout poses test

    Public health officials, as well as drugmakers, are trying to raise awareness of RSV among older adults at risk, and convince them to get an additional respiratory shot alongside those for COVID-19 and flu.

    By Sept. 18, 2023
  • Explore the Trendline
    Image attribution tooltip
    Brian Tucker / BioPharma Dive
    Image attribution tooltip
    Trendline

    Pharma, new drugs and market strategy

    New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.

    By BioPharma Dive staff
  • FDA approves GSK’s new bone cancer drug, helping validate a billion-dollar bet

    The drug, known scientifically as momelotinib, is now cleared to treat myelofibrosis and will compete against rival medicines sold by Incyte and Bristol Myers Squibb.

    By Sept. 18, 2023
  • Johnson & Johnson's new logo is seen on an office lobby wall.
    Image attribution tooltip
    Courtesy of Johnson & Johnson
    Image attribution tooltip

    J&J to phase out Janssen name in corporate rebrand

    Janssen will be recast as Johnson & Johnson Innovative Medicine, melding the drugs division’s identity more closely with its parent.

    By Sept. 15, 2023
  • A person holds a rectangular device connected to tubing.
    Image attribution tooltip
    dzika_mrowka via Getty Images
    Image attribution tooltip

    Insulin pump-makers grapple with questions about GLP-1s

    New weight loss drugs have sparked a stock selloff for some device makers, but medtech analysts don’t see them a likely to undermine the companies’ business — yet. 

    By Elise Reuter • Sept. 14, 2023
  • Akili's digital therapeutic, EndeavorRx, involves navigating obstacles in different courses. It's intended to improve attention.
    Image attribution tooltip
    Courtesy of Akili Interactive
    Image attribution tooltip

    Akili cuts 40% of workforce, plans shift to non-prescription model

    The digital therapeutics company expects to extend its cash runway into 2025 with the changes.

    By Elise Reuter • Sept. 13, 2023
  • A podium showing the logo for the Centers for Disease Control and Prevention is seen.
    Image attribution tooltip
    Kevin C. Cox via Getty Images
    Image attribution tooltip

    CDC endorses new COVID boosters as focus turns to rollout

    This fall will now feature vaccination campaigns for COVID-19, influenza and respiratory syncytial virus.

    By Sept. 13, 2023
  • Ocean waves
    Image attribution tooltip
    Permission granted by LukaszDesign
    Image attribution tooltip
    Sponsored by Alexander Group

    Do not miss the return to growth

    The signals of a return to growth are emerging. As commercial leaders gear up for 2024 planning, they must prepare to fight for resources in a budget constrained environment.

    By Alexander Group • Sept. 5, 2023
  • An outside view of an Amgen building.
    Image attribution tooltip
    Amgen Inc.
    Image attribution tooltip

    FTC allows Amgen’s $28B deal for Horizon to go through, with conditions

    The settlement between Amgen and the FTC may reassure those in the industry who feared a more activist regulator would gum up dealmaking.

    By Sept. 1, 2023
  • Image attribution tooltip
    Brian Tucker / BioPharma Dive
    Image attribution tooltip

    FTC pulls back on legal challenge to Amgen’s $28B bid for Horizon

    Urged by a judge, the antitrust regulator said it wants to start discussions “regarding the proper resolution of this matter” — a potential prelude to a settlement.

    By Aug. 28, 2023
  • Corporate logos are seen outside  on May 15, 2006, in Macclesfield, England.
    Image attribution tooltip
    Christopher Furlong via Getty Images
    Image attribution tooltip

    AstraZeneca the latest pharma to challenge drug pricing law

    The drugmaker's lawsuit follows similar legal challenges from Merck & Co., Bristol Myers Squibb and Johnson & Johnson, among others. 

    By Aug. 25, 2023
  • Image attribution tooltip
    Novartis
    Image attribution tooltip

    FDA approves Novartis’ copycat of blockbuster Biogen drug

    According to one analyst, the approval was the last hurdle keeping Sandoz’s Tyruko from directly competing in the U.S. market against Biogen’s inflammation-regulating medicine Tysabri.

    By Updated Aug. 25, 2023
  • Boehringer sues to block US drug price program

    The pharma’s suit, which claims Medicare’s new power to negotiate certain drug prices is unconstitutional, comes days before the agency will reveal the first 10 medicines to be included under the plan.

    By Aug. 22, 2023
  • Amazon Pharmacy
    Image attribution tooltip
    Courtesy of Amazon
    Image attribution tooltip

    Amazon Pharmacy expands insulin manufacturer coupons

    The new coupons include some of the most commonly prescribed diabetes drugs from Eli Lilly, Novo Nordisk and Sanofi.

    By Rebecca Pifer • Aug. 17, 2023
  • Nick Jonas poses in front of a glowing background, wearing a small, round device on his upper arm
    Image attribution tooltip
    Courtesy of Dexcom
    Image attribution tooltip

    Dexcom, Abbott ramp up DTC marketing in fight for growing diabetes market

    As insurers cover continuous glucose monitors for more people, device makers are taking a page from the pharma marketing playbook.

    By Elise Reuter • Aug. 17, 2023
  • The logo of Amylyx Pharmaceuticals is seen through an office window.
    Image attribution tooltip
    Permission granted by Amylyx Pharmaceuticals
    Image attribution tooltip

    Amylyx ALS drug sales tick higher after fast US launch

    In Europe, however, the biotech is appealing a negative decision from regulators that has for now blocked its path to market there.

    By Aug. 11, 2023
  • The European Union flag.
    Image attribution tooltip
    artJazz via Getty Images
    Image attribution tooltip

    Novartis sickle cell drug’s approval formally revoked by EU regulators

    The company said it would withdraw the drug, Adakveo, from the EU market after the European Commission endorsed an earlier EMA recommendation.

    By Aug. 4, 2023
  • Packaging for Perrigo's over-the-counter birth control Opill
    Image attribution tooltip
    Courtesy of Perrigo
    Image attribution tooltip
    Q&A

    With OTC birth control approved, access battles have just begun

    Perrigo received the first FDA approval for an over-the-counter birth control pill. Now, its global VP of women’s health says the company is working on the next challenge — affordability.  

    By Karissa Waddick • July 31, 2023
  • An image of Apellis Pharmaceuticals' vision loss drug Syfovre
    Image attribution tooltip
    Courtesy of Apellis Pharmaceuticals
    Image attribution tooltip

    Apellis faces safety doubts for fast-selling eye drug

    At a medical meeting, the company confirmed seven cases of a rare, but severe, side effect have been reported following treatment with its geographic atrophy drug Syfovre.

    By Updated July 31, 2023
  • An image of Apellis Pharmaceuticals' vision loss drug Syfovre
    Image attribution tooltip
    Courtesy of Apellis Pharmaceuticals
    Image attribution tooltip

    Apellis shares sink on reports of rare side effects with new vision loss drug

    An organization of retinal specialists flagged six cases of severe eye inflammation from commercial use of Syfovre. Apellis says the drug’s safety profile is consistent with testing.

    By July 17, 2023
  • A Roche logo is seen on the side of a building.
    Image attribution tooltip
    Courtesy of Roche
    Image attribution tooltip

    More convenient form of Roche MS drug succeeds in study

    The under-the-skin formulation of Ocrevus can be administered in 10 minutes, versus a longer period for the current intravenous version.

    By Kristin Jensen • July 13, 2023
  • Boxes of the diabetes drug Ozempic rest on a pharmacy counter.
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip
    Obesity drugs

    EMA expands probe of possible suicide risk to popular weight loss, diabetes drugs

    The European drug regulator says it now has 150 reports of possible cases involving self-injury and suicidal thoughts among people taking GLP-1 medicines like Ozempic.

    By Kristin Jensen • July 12, 2023
  • The European Union flag.
    Image attribution tooltip
    artJazz via Getty Images
    Image attribution tooltip

    Illumina hit by EU with maximum fine for Grail acquisition

    The European Commission called Illumina’s closing of the deal without its approval an “unprecedented” move that undermines its system for regulating the competitive landscape.

    By Susan Kelly • July 12, 2023
  • Contact solution sold by Bausch + Lomb sits on a store shelf.
    Image attribution tooltip
    Justin Sullivan via Getty Images
    Image attribution tooltip

    Bausch + Lomb bulks up OTC business with J&J deal

    The eye care company has become an active acquirer under new CEO Brent Saunders, buying an eye drop product line one week after purchasing several medicines from Novartis.

    By July 6, 2023
  • Workers gather inside BioMarin’s gene therapy manufacturing plant in Novato, California.
    Image attribution tooltip
    Courtesy of BioMarin Pharmaceutical
    Image attribution tooltip

    With FDA approval in hand, BioMarin lays out plan to sell $2.9M gene therapy

    The agency granted a long-awaited clearance last Thursday, but unexpected aspects of the hemophilia treatment’s label had some investors worried about its commercial prospects.

    By June 30, 2023